Mitochondria mediate diverse cellular functions including energy generation and ROS (reactive oxygen species) production and contribute to signal transduction. Mitochondria are also key regulators of cell viability and play a central role in necrotic and apoptotic cell death pathways induced by cardiac ischaemia/reperfusion injury. PKC (protein kinase C) ε plays a critical role in cardioprotective signalling pathways that protect the heart from ischaemia/reperfusion. Emerging evidence suggests that the cardioprotective target of PKCε resides at the mitochondria. Proposed mitochondrial targets of PKCε include mitoK ATP (mitochondrial ATP-sensitive K + channel), components of the MPTP (mitochondrial permeability transition pore) and components of the electron transport chain. This review highlights mitochondrial targets of PKCε and their possible role in cardioprotective signalling in the setting of ischaemia/reperfusion injury.
Introduction
Myocardial ischaemia occurs when blood flow to the heart is impaired, such as during AMI (acute myocardial infarction) or coronary bypass surgery. Restoration of coronary blood flow (reperfusion) is a prerequisite for the survival of ischaemic myocardium. Paradoxically, reperfusion of ischaemic tissue exacerbates injury, and results in necrotic and apoptotic death of cells that were only moderately injured during the preceding ischaemic insult. The most potent known mechanism of protecting the heart from ischaemia/reperfusion is by 'preconditioning' the heart with brief periods of intermittent ischaemia and reperfusion prior to the sustained ischaemic event [1] . IPC (ischaemic preconditioning) initiates intracellular signalling pathways, which increase cellular resistance to ischaemia/reperfusion, thus reducing infarct size.
Our laboratory previously found that activation of the PKCε [ε isoenzyme of PKC (protein kinase C)] is critical for conferring the cardioprotective phenotype of IPC. We identified isoenzyme-specific PKC activators, based on intramolecular interactions within each PKC isoenzyme, and isoenzyme-specific inhibitors, based on intermolecular interactions between each PKC isoenzyme and its respective isoenzyme-selective anchoring protein, termed RACKs (receptors for activated C-kinase), to which it binds upon activation (reviewed in [2] ). We found that selective activation of PKCε confers cardiac protection, whereas selective inhibition of PKCε abolishes protection induced by IPC [3, 4] . These findings have been repeated in numerous cellular models, in ex vivo hearts and in vivo (reviewed in [5] ).
On activation, PKCε translocates to multiple subcellular sites. Previous studies suggest that mitochondrial translocation of PKCε is required for cardioprotection [6] . Furthermore, there is an emerging body of evidence that suggests that PKCε substrates reside within cardiac mitochondria [6] [7] [8] [9] [10] [11] [12] . Cardiac mitochondria comprise approx. 30-40% of the volume of cardiac myocytes and generate most of the ATP required to meet the energy demand of the heart [13] . Mitochondria also play an important role in intracellular signalling through the generation of ROS (reactive oxygen species) and regulation of intracellular Ca 2+ signalling during periods of metabolic stress [13] . Additionally, mitochondria are centrally involved in mediating both necrotic and apoptotic cell death pathways activated by ischaemia/ reperfusion and are thus a major target for developing novel cardioprotective therapeutics [13] . This article will review mitochondrial targets of PKCε and discuss their role in protecting the heart from ischaemia/reperfusion.
Mitochondrial targets of PKCε
Multiple mitochondrial targets of PKCε have been reported, including those regulating oxidative phosphorylation, ROS generation and mitochondrial ion transport [6] [7] [8] [9] [10] [11] [12] (Figure 1) . Analysis of the subcellular distribution of PKCε in mice with cardiac-specific expression of constitutively active PKCε revealed that activated PKCε forms signalling complexes with a variety of mitochondrial proteins [14] . Interestingly, in wildtype hearts, PKCε was concentrated in the periphery of the mitochondria, whereas in constitutively active PKCε hearts, PKCε was present in the mitochondrial matrix [14] . In this study [14] , the mechanism for increased mitochondrial matrix PKCε was not investigated. However, the authors speculated that placing PKCε in its active state (mutation of Ala 159 to
Figure 1 Proposed mitochondrial cardioprotective targets of PKCε
Cellular PKCε resides in the cytosol until stimulation by the phospholipid-derived second messenger DAG (diacylglycerol), which is downstream from GPCR (G-protein-coupled receptor) stimulation by adenosine, which accumulates in the ischaemic heart. On activation, PKCε translocates to the mitochondria where it phosphorylates multiple targets that confer protection against cardiac ischaemia. These include (i) inhibition of MPTP opening, (ii) potentiation of mitoK ATP (mKATP) channel opening and (iii) increased ATP production through regulation of COIV activity. IR, ischaemia/reperfusion.
glutamic acid residue in the PKCε pseudosubstrate region) may have facilitated its mitochondrial import [14] . Other studies have identified COIV (cytochrome c oxidase subunit IV) as a substrate for PKCε [7, 9] . In vitro phosphorylation of COIV, induced by PMA, is blocked by the selective PKCε inhibitor εV1-2 [9] . Furthermore, hypoxic preconditioning of neonatal cardiomyocytes induces co-precipitation of PKCε and COIV, resulting in phosphorylation of COIV and a 4-fold increase in cytochrome c oxidase activity [7] , which was attenuated by εV1-2. These findings suggest that PKCε interacts with COIV in cardiac mitochondria to enhance electron transport chain activity, modulating myocardial bioenergetics and increasing ATP synthesis, thus providing enhanced resistance to ischaemic injury. Another proposed mitochondrial target for PKCε is the MPTP (mitochondrial permeability transition pore). The MPTP is a large-conductance, mitochondrial 'mega-pore' that remains tightly closed under normal conditions, but which opens during reperfusion, resulting in necrotic cell death (reviewed in [13] ). It is predicted that the pore may be composed of the ANT (adenine nucleotide translocase) in the IMM (inner mitochondrial membrane), the VDAC (voltagedependent anion channel) in the OMM (outer mitochondrial membrane) and cyclophilin D in the mitochondrial matrix [13] . However, the exact structure of the MPTP is unknown and other mitochondrial proteins may mediate the mitochondrial permeability transition [13] . PKCε has been demonstrated to interact with putative components of the MPTP in heart mitochondria [10] . Immunoprecipitation of mouse cardiac mitochondria revealed that PKCε physically associates with both ANT and VDAC and that PKCε can phosphorylate VDAC [10] . Furthermore, MPTP opening could be reduced by incubation of cardiac mitochondria with recombinant PKCε and was suppressed in mitochondria isolated from constitutively active PKCε hearts [10] . Thus PKCε can regulate MPTP opening, conferring protection from reperfusion-induced necrotic cell death.
Another postulated mitochondrial target of PKCε is the mitoK ATP (mitochondrial ATP-sensitive K + channel) located in the IMM. These channels are closed under normal conditions, but are opened during periods of metabolic stress as ATP levels decline. Although the mechanism is unknown, numerous studies have demonstrated that opening of mitoK ATP channels exerts a cardioprotective phenotype, which is thought to be due to regulation of mitochondrial matrix volume, Ca 2+ levels or ROS production as a result of increased mitochondrial K + flux [13] . Recent studies have demonstrated that PKCε interacts with mitoK ATP at the IMM [11] , and channel opening in isolated mitochondria could be induced by application of the PKC isoenzyme-selective agonist, ψεRACK, and blocked by the PKCε antagonist, εV1-2 [11] . These studies suggest that mitochondrial PKCε may also contribute to cardioprotection by regulation of mitoK ATP channel opening. Identification of the molecular components of the mitoK ATP is necessary to reveal the PKCε phosphorylation site.
Summary and future directions
There is accumulating evidence to suggest that the cardioprotective target of PKCε resides within cardiac mitochondria [6] [7] [8] [9] [10] [11] . Numerous groups have identified intramitochondrial targets that are PKCε substrates, including components of the electron transport system [7, 9] , the MPTP [10] and mitoK ATP channels [11] . Studies have demonstrated that PKCε is constitutively present within cardiac mitochondria [11] , while others have found that mitochondrial PKCε translocation is required to confer resistance against metabolic stress [6, 7, 12] .
The discovery of mitochondrial PKCε substrates has raised some important questions that may direct future research. First, to reach intramitochondrial substrates, PKCε must traverse the mitochondrial membranes. In order to do this, there must be a mitochondrial import mechanism to permit PKCε translocation into mitochondria. Apart from a small number of proteins encoded by the mitochondrial genome, most mitochondrial proteins are nuclear-encoded and synthesized in the cytosol [15] . They are subsequently imported into mitochondria via the TOM (translocase of the outer membrane) and TIM (translocase of the inner membrane) mitochondrial import machinery [15] . Constitutively active PKCε is reported to be present inside cardiac mitochondria, suggesting that mitochondrial import of PKCε requires the enzyme to be in the open/active configuration [14] . Future research should be aimed at identifying the machinery responsible for PKCε import.
Secondly, it is interesting to speculate whether there is a mitochondrial RACK for PKCε. Certainly, the evidence would support this hypothesis as the εV1-2 peptide, which blocks PKCε binding to its RACK, is effective at blocking PKCε-mediated events in isolated mitochondria [7, 11] . We previously identified β COP (β coatamer protein) as the RACK for PKCε [16] , and it would be interesting to determine whether this is also the mitochondrial RACK or whether there are alternative anchoring proteins within mitochondria. Further studies employing mitochondrial subfractionation and electron microscopy should be undertaken to resolve these issues.
Thirdly, if mitochondrial import of PKCε is necessary to evoke cardioprotection, is import the rate-limiting step that governs the protective outcome of IPC? Recent evidence suggests that components of the mitochondrial import machinery are down-regulated during ischaemia but preserved by IPC [17] . It could thus be hypothesized that an IPCinduced stimulation of mitochondrial import may account for the increased intramitochondrial PKCε induced by IPC. Further work is required to resolve these issues; however, it is likely that modulation of mitochondrial function by PKCε represents an important component of the endogenous cardioprotective response of the heart to ischaemic injury.
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